Results 131 to 140 of about 22,351 (243)

Extracellular Vesicles as Drivers of Lung Endothelial Dysfunction in ARDS: Mechanisms and Therapeutic Opportunities

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
This review summarizes how extracellular vesicles from diverse pulmonary and extrapulmonary sources contribute to endothelial dysfunction in ARDS and evaluates emerging endothelial‐targeted therapies for their potential to mitigate EV‐mediated pathogenic mechanisms.
Mohammed Yaman Al Matni, Patrick Belvitch, Steven M. Dudek, Eleftheria Letsiou   +3 more
wiley   +1 more source

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1565-1573, June 2026.
There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh, Ofek Levi, Nili Stein, Amir Yahav, Naomi Gronich   +4 more
wiley   +1 more source

Organoids: From Bench to Bedside Applications

MedComm, Volume 7, Issue 6, June 2026.
Organoids, as a groundbreaking biomedical research platform, utilize adult stem cells (ASCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) as sources. By integrating specific growth and differentiation signals within an extracellular matrix (e.g., Matrigel), organoids guide cells to self‐assemble into three‐dimensional ...
Kelin Li, Rui Cao, Maochen Li, Zichao Tian, Huahao Fan, Bixia Hong, Xiaojuan Liu   +6 more
wiley   +1 more source

Population Pharmacokinetics of Fingolimod Phosphate in Healthy Participants.

, 2011
Fingolimod (FTY720) is a sphingosine 1-phosphate receptor (S1PR) modulator currently being evaluated for the treatment of multiple sclerosis. Fingolimod undergoes phosphorylation in vivo to yield fingolimod phosphate (fingolimod-P), which modulates S1PRs
Wu, Kai, Mercier, Francois, David, Olivier J, Robert L. Schmouder, Francois Mercier, Kai Wu, Looby, Michael, Michael Looby, Schmouder, Robert L, Olivier J. David   +9 more
core   +1 more source

Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice

, 2011
Background: FTY720, an immunomodulator derived from a fungal metabolite which reduces circulating lymphocyte counts by increasing the homing of lymphocytes to the lymph nodes has recently gained interest in stroke research.
Czech-Zechmeister, Bozena, Pfeilschifter, Josef (Prof. Dr.), Bożena Czech-Zechmeister, Marian Sujak, Thomas A Wichelhaus, Sujak, Marian, Christian Foerch, Pfeilschifter, Waltraud, Josef Pfeilschifter, Wichelhaus, Thomas Alexander, Förch, Christian, Waltraud Pfeilschifter   +11 more
core   +1 more source

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

MedComm, Volume 7, Issue 6, June 2026.
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele, Ajit Manchare, Swapnali Parit, Amol D. Gholap, Krishna Jadhav, Navnath Hatvate, Keshav Raj Paudel, Satish Rojekar   +7 more
wiley   +1 more source

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

Med Research, Volume 2, Issue 2, Page 236-279, June 2026.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang, Ge Zhang, Tian‐Ding Liu, Tianshu Gu, Fengyi Yu, Pengyuan Xu, Wunan Mi, Xuanjiang Zhao, Qian Guo, Honglin Zheng, Taiqi Zhao, Qiang Li, Di Lu, Mingxuan Duan, Chaoyang Yu, Ruhao Wu, Shiqian Zhang, Haonan Zhang, Zeyu Wang, Youyang Zheng, Yan Xiao, Zenglei Zhang, Ge Zhang   +22 more
wiley   +1 more source

Life-threatening asthma attack during prolonged fingolimod treatment: case report

, 2014
Chiara Zecca,1,* Matteo Caporro,1,* Sandor Györik,2 Claudio Gobbi11Neurocenter of Southern Switzerland, Department of Neurology, Ospedale Regionale di Lugano, Lugano, Switzerland; 2Department of Internal Medicine, Ospedale Regionale di Bellinzona ...
Zecca C, Györik S, Gobbi C, Caporro M   +3 more
core  

Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations

Neurological Therapeutics, 2019
Because the treatment of multiple sclerosis (MS) may span decades, the need often arises to make changes to the treatment plan in order to accommodate changing circumstances.
B. Barry, April A. Erwin, J. Stevens, C. Tornatore   +3 more
semanticscholar   +1 more source

Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4‐Year CASTING–LIBERTO Trial

European Journal of Neurology, Volume 33, Issue 6, June 2026.
ABSTRACT Background Almost 75% of patients with relapsing multiple sclerosis (pwRMS) with suboptimal response to other disease‐modifying therapies (DMTs) showed no evidence of disease activity (NEDA‐3) when treated with ocrelizumab in a large single‐arm multicentre trial over 2 years.
Patrick Vermersch, Ralph H. B. Benedict, Bart Van Wijmeersch, Gary Cutter, llya Kister, Celia Oreja‐Guevara, Aksel Siva, Heinz Wiendl, Jens Wuerfel, Bouchra El Azzouzi, Thomas Kuenzel, Regine Buffels, Licinio Craveiro, Petra Dirks, Giancarlo Comi   +14 more
wiley   +1 more source